Nivolumab (Opdivo®) is an immunotherapy drug that has already been approved for the treatment of advanced kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
However, this drug is not yet used for patients with localized kidney cancer.
The current standard of care for patients with localized kidney cancer is nephrectomy, followed by active surveillance. This means that your doctor will monitor your recovery closely with regular tests and scans, but you will not receive any new drugs or therapies until there are signs that your cancer has returned.
This study will investigate whether Nivolumab, when administered before and after nephrectomy, can improve surgical outcomes. Specifically, whether the Nivolumab is able to delay or prevent cancer from returning in patients who have recently had their kidney removed.
Accordingly, patients will be randomly assigned to one of two groups:
- Group 1 will receive two rounds of Nivolumab prior to their surgery, followed by a maintenance schedule given every 2-4 weeks for a maximum of 12 rounds.
- Group 2 will receive the standard of care treatment currently employed in Canada: nephrectomy followed by active surveillance only.
Both groups will be monitored for up to 10 years post-surgery to determine whether Nivolumab had any significant effect on surgical outcome.
- Any subtype
- Cancer must be confined to the kidney
- No prior treatments are permitted
- No drug therapy (i.e. Sunitinib (Sutent®))
- No radiation therapies
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreTom Baker Cancer Centre||Principal InvestigatorDr. Daniel Heng||LocationCalgary, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorDr. Naveen Basappa||LocationEdmonton, AB||Trial StatusSuspended|
|Hospital / Cancer CentreCancerCare Manitoba||Principal InvestigatorDr. Jeffrey Graham||LocationWinnipeg, MB||Trial StatusSuspended|
|Hospital / Cancer CentreWindsor Regional Cancer Centre||Principal InvestigatorDr. Sindu Kanjeekal||LocationWindsor, ON||Trial StatusSuspended|
|Hospital / Cancer CentreLondon Regional Cancer Program||Principal InvestigatorDr. Nicholas Power||LocationLondon, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSaint Joseph's Healthcare||Principal InvestigatorDr. Anil Kapoor||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorDr. Anil Kapoor||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSaint Catharines General||Principal InvestigatorDr. Michael Levesque||LocationSaint Catharines, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Hospital||Principal InvestigatorDr. Antonio Finelli||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOdette Cancer Centre- Sunnybrook Health Sciences Centre||Principal InvestigatorDr. Martin Smoragiewicz||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreKingston Health Sciences Centre||Principal InvestigatorDr. Francisco Badilo||LocationKingston, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreCentre Hospitalier de l'Universite de Montreal||Principal InvestigatorDr. Jean-Baptiste Lattouf||LocationMontreal, QC||Trial StatusSuspended|
|Hospital / Cancer CentreCentre Hospitalier Universitaire de Sherbrooke-Fleurimont||Principal InvestigatorDr. Michael Pavic||LocationSherbrooke, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreThe Moncton Hospital||Principal InvestigatorDr. Mahmoud Abdelsalam||LocationMoncton, NB||Trial StatusRecruiting|
|Hospital / Cancer CentreQEII Health Sciences Centre||Principal InvestigatorDr. Lori Wood||LocationHalifax, NS||Trial StatusRecruiting|